<DOC>
	<DOCNO>NCT00468884</DOCNO>
	<brief_summary>Context : Oral formulation GLP-1 PYY3-36 , two satiety peptide , study . An oral delivery system would preferable many possible therapeutic indication peptide . Objectives : Our objective establish pharmacological profile increase oral dos GLP-1 PYY3-36 healthy volunteer . In addition , pharmacological effect GLP-1 investigate . Setting : Single center escalate dose study oral application . Subjects Methods : In first part , GLP-1 give orally 6 male subject ; treatment consist one follow oral dos either GLP-1 ( 0.5 , 1.0 , 2.0 4.0 mg ) placebo . In second part , PYY3-36 give orally another 6 healthy male subject ; treatment consist one follow oral dos either PYY3-36 ( 0.25 , 0.5 , 1.0 , 2.0 4.0 mg ) placebo .</brief_summary>
	<brief_title>Oral Administration Peptides ; Absorption From Gastrointestinal Tract</brief_title>
	<detailed_description>The study conduct phase I , open , placebo-controlled , dose-escalating study . In part I , six treatment , separate least 7 day , perform 6 male subject ; treatment consist one oral dose GLP-1 ( 7-36 amide ) ( 0.5 , 1.0 , 2.0 , 4 mg ) placebo ; last treatment intravenous infusion GLP-1 give 45 min ( 0.4 pmol/kg per min infuse 45 min ) . The treatment identical design except oral dose GLP-1 . In part II , six oral treatment , separate least 7 day , give additional 6 male subject ; treatment consist one oral dose PYY3-36 ( 0.25 , 0.5 , 1.0 , 2.0 , 4 mg ) placebo ; intravenous infusion PYY3-36 could give GMP conform PYY3-36 available use human . Blood drawn regular interval EDTA tube contain aprotinin ( 500 kIU/ml blood ) DPP-IV inhibitor hormone determination : -30 , -15 , 0 , 15 , 30 , 45 , 60 , 75 , 90 , 120 , 150 , 180 , 240 , 300 min .</detailed_description>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>healthy male female</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Kinetics GLP-1 PYY3-36 ; increase oral dos</keyword>
</DOC>